Abstract:
Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.
Abstract:
The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.
Abstract:
Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.
Abstract:
A die casting process using pattern recognition techniques to identify those die castings manufactured under conditions likely to produce a die casting which would subsequently prove unacceptable for use. By promptly identifying such die castings, they may be discarded before being shipped to a remote facility for further processing. As a result, the rejection rate of die castings at the remote facility may be reduced and the raw materials used to form the discarded die castings may be more readily recycled.
Abstract:
A battery pack has series-parallel connected battery cells. An inrush current limiting circuit has current limiting devices and a current limiting tracking means limits inrush current from shorted battery cells. Each current limiting tracking means is coupled to the current limiting devices such that they limit an inrush current from parallel neighbor battery cells when one battery cell on the column shorts. The current limiting devices are variable buffer resistors with a positive temperature coefficient. The current limiting tracking means are heat sinks that thermally couples the buffer resistors together such that the buffer resistors increase in resistance with a temperature increase caused by current flowing through the buffer resistor associated with the shorted battery cell. Current regulating elements are in series with columns of battery cells for preventing inrush current to the columns of the battery cells.
Abstract:
Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Abstract:
The present invention provides an n-bits successive approximation register (SAR) analog-to-digital converting (ADC) circuit, comprising: an n-bits SAR control logic, a p-type capacitor network including a DACp array and a sampling capacitor CSp, an n-type capacitor network including a DACn array and a sampling capacitor CSn; and a comparator for comparing outputs from the p-type capacitor network and the n-type capacitor network, wherein a power supply and ground are directly connected to the p-type capacitor network and the n-type capacitor network without using reference voltages produced by a reference voltage generator. The n-bits SAR control logic comprises n shift registers, n bit registers, and a switching logic. The comparator comprises a first pre-amplifier, a second pre-amplifier and a dynamic latch. Alternative, the comparator comprises a four-input pre-amplifier and a dynamic latch.
Abstract:
Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.
Abstract:
A die casting process using pattern recognition techniques to identify those die castings manufactured under conditions likely to produce a die casting which would subsequently prove unacceptable for use. By promptly identifying such die castings, they may be discarded before being shipped to a remote facility for further processing. As a result, the rejection rate of die castings at the remote facility may be reduced and the raw materials used to form the discarded die castings may be more readily recycled.
Abstract:
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.